Joon Won Yoon

Joon Won Yoon

Auto-generated profile, based on publicly available information

Joon Won Yoon

Department of Biological Sciences, Sookmyung Women's University, Seoul 04310, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Development
Verified
Journal Article
Open access
PDF file
JEJoshua Everson
Joshua Everson
DFDustin M. Fink
Dustin M. Fink
JYJoon Won Yoon
Joon Won Yoon
ELElizabeth J. Leslie
Elizabeth J. Leslie
HKHenry Walker Kietzman
Henry Walker Kietzman
RLRobert J. Lipinski
Robert J. Lipinski
Cleft lip is one of the most common human birth defects, yet our understanding of the mechanisms that regulate lip morphogenesis is limited. Here, we show that Sonic Hedgehog (Shh)-induced proliferation of cranial neural crest cell (cNCC) mesenchyme is required for upper lip closure. Gene expression profiling revealed a subset of Forkhead box (Fox) genes regulated by Shh signaling during lip morphogenesis. During cleft pathogenesis, reduced proliferation in the medial nasal process mesenchyme paralleled the domain of reduced Foxf2 and Gli1 expression. SHH ligand induction of Foxf2 expression was dependent upon Shh pathway effectors in cNCCs, while a functional GLI binding site was identified downstream of Foxf2. Consistent with the cellular mechanism demonstrated for cleft lip pathogenesis, we found that either SHH ligand addition or FOXF2 overexpression is sufficient to induce cNCC proliferation. Finally, analysis of a large multi-ethnic human population with cleft lip identified clusters of single-nucleotide polymorphisms in FOXF2. These data suggest that direct targeting of Foxf2 by Shh signaling drives cNCC mesenchyme proliferation during upper lip morphogenesis, and that disruption of this sequence results in cleft lip.

1 August 2017 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
JWJoon Yeon Won
Joon Yeon Won
WJWoo Young Jang
Woo Young Jang
HLHye-Ran Lee
Hye-Ran Lee
SPSeon Young Park
Seon Young Park
WKWoo-Young Kim
Woo-Young Kim
TCTae-Joon Cho
Tae-Joon Cho

3 April 2023
Verified
Other
Open access
JYJoon Won Yoon
Joon Won Yoon
MGMarisa Gallant
Marisa Gallant
MLMarilyn Lg Lamm
Marilyn Lg Lamm
SIStephen Iannaccone
Stephen Iannaccone
KVKarl-Frederic Vieux
Karl-Frederic Vieux
DWDavid Walterhouse
David Walterhouse
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.

3 April 2023
Verified
Other
Open access
JYJoon Won Yoon
Joon Won Yoon
MGMarisa Gallant
Marisa Gallant
MLMarilyn Lg Lamm
Marilyn Lg Lamm
SIStephen Iannaccone
Stephen Iannaccone
KVKarl-Frederic Vieux
Karl-Frederic Vieux
DWDavid Walterhouse
David Walterhouse
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.